UNSPSC 51263008: Dapiprazole monohydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H27N5.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DS9UJN1I0X, chemically known as 1,2,4-triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-, monohydrochloride, but more generally known as dapiprazole monohydrochloride, which bears US NIH Compound Identifier 91269.

European Medicines Agency schedules dapiprazole monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06906MIG. Most nations, for tariff purposes, schedule dapiprazole monohydrochloride under HS 29335995. SMILES: CC1CCCCC1N2CCN(CC2)CCC3NNC4N3CCCC4.CL.

UNSPSC 51263008 Dapiprazole monohydrochloride is a Commodity code for a specific ophthalmic pharmaceutical product, yet the recent state and local opportunities posted under this code do not align with its nominal scope. The Seminole County, Florida IFB solicits naloxone and drug deactivation systems for community health initiatives, and the Texas Health and Human Services Commission RFI seeks direct-to-manufacturer prescription program capabilities — neither procurement involves dapiprazole monohydrochloride or its clinical application. The code shows little relevant recent activity grounded in its pharmaceutical designation.

The geographic reach captured in the recent-opportunities block spans Florida and Texas, though the fundamental mismatch between the code's intended product category and the actual solicitations posted beneath it suggests either a data-entry error in the tagging of these opportunities or a broader indexing issue within the state and local procurement system. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) represents a standard county health procurement through competitive sealed bidding with quarterly delivery requirements, while the Texas HHS RFI (HHS0017013, response deadline April 3, 2026) functions as preliminary market research into direct pharmaceutical contracting models. Neither is actionable under the dapiprazole code as typically understood, and firms pursuing this commodity should verify the accuracy of code assignments in future solicitations before committing business development resources.